PPARδ调节剂ASP1128对心脏术后急性肾损伤风险患者的作用
一项随机、双盲、安慰剂对照、生物标志物分组驱动的多中心研究纳入150例心脏术后急性肾损伤风险成人患者,比较每日一次静脉注射100 mg ASP1128与安慰剂共3天的疗效与安全性。结果显示ASP1128安全且耐受良好,但未在肾脏终点显示疗效。
要点
- ASP1128组与安慰剂组术后72小时内基于血清肌酐的急性肾损伤发生率无显著差异(24.6% vs 21.0%,P=0.595)。
- ASP1128安全且耐受良好,但未在肾脏终点显示疗效。
- ASP1128组术后心房颤动发生率(11.6%)低于安慰剂组(29.6%)。
核心结论
- ASP1128在心脏术后急性肾损伤风险患者中安全且耐受良好,但未在肾脏终点显示疗效。
研究设计与样本
- 随机、双盲、安慰剂对照、生物标志物分组驱动的多中心研究,纳入150例心脏术后急性肾损伤风险成人患者,按1:1随机接受每日一次静脉注射100 mg ASP1128或安慰剂共3天(ASP1128组69例,安慰剂组81例)。
主要发现
- 术后72小时内基于血清肌酐的急性肾损伤发生率在安慰剂组为21.0%,ASP1128组为24.6%(P=0.595)。
- 术后72小时内中重度急性肾损伤(2/3期基于血清肌酐和/或3期基于尿量标准)发生率在安慰剂组为19.8%,ASP1128组为23.2%(P=0.609)。
- 30天内主要不良肾脏事件(MAKE)发生率在安慰剂组为11.1%,ASP1128组为13.0%(P=0.717)。
- 90天内主要不良肾脏事件发生率在安慰剂组为9.9%,ASP1128组为15.9%(P=0.266)。
- 未发现ASP1128治疗相关的安全性问题,但术后心房颤动发生率在ASP1128组为11.6%,低于安慰剂组的29.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Peroxisome proliferator-activated receptor δ (PPARδ) plays a central role in modulating mitochondrial function in ischemia-reperfusion injury. The novel PPARδ modulator, ASP1128, was evaluated. METHODS: A randomized, double-blind, placebo-controlled, biomarker assignment-driven, multicenter study was performed in adult patients at risk for acute kidney injury (AKI) following cardiac surgery, examining efficacy and safety of a 3-day, once-daily intravenous dose of 100 mg ASP1128 versus placebo (1:1). AKI risk was based on clinical characteristics and postoperative urinary biomarker (TIMP2)•(IGFBP7). The primary end point was the proportion of patients with AKI based on serum creatinine within 72 hours postsurgery (AKI-SCr72h). Secondary endpoints included the composite end point of major adverse kidney events (MAKE: death, renal replacement therapy, and/or ≥25% reduction of estimated glomerular filtration rate [eGFR]) at days 30 and 90). RESULTS: A total of 150 patients were randomized and received study medication (81 placebo, 69 ASP1128). Rates of AKI-SCr72h were 21.0% and 24.6% in the placebo and ASP1128 arms, respectively (P = 0.595). Rates of moderate/severe AKI (stage 2/3 AKI-SCr and/or stage 3 AKI-urinary output criteria) within 72 hours postsurgery were 19.8% and 23.2%, respectively (P = 0.609). MAKE occurred within 30 days in 11.1% and 13.0% in the placebo and ASP1128 arms (P = 0.717), respectively; and within 90 days in 9.9% and 15.9% in the placebo and ASP1128 arms (P = 0.266), respectively. No safety issues were identified with ASP1128 treatment, but rates of postoperative atrial fibrillation were lower (11.6%) than in the placebo group (29.6%). CONCLUSION: ASP1128 was safe and well-tolerated in patients at risk for AKI following cardiac surgery, but it did not show efficacy in renal endpoints.
引用
- van Till JWO, Nojima H, Kameoka C, et al. The Effects of Peroxisome Proliferator-Activated Receptor-Delta Modulator ASP1128 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. Kidney Int Rep. 2023. PMID: 37441472. doi:10.1016/j.ekir.2023.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。